Genentech & Adaptive’s TCR Strategy, Arch’s New Cell Therapy Co, & Esperion’s Rich EU Deal

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.